Epizyme Inc (EPZM)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139

Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Srl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate.

Data as of 2020-06-27
Market Cap1.567 Billion Shares Outstanding101.061 Million Avg 30-day Volume1.462 Million
P/E Ratio Dividend Yield EPS-2.04
Price/Sales90.799 Price cash flow ratio31.1 Price free cash flow ratio-8.4
Book Value3.01 Price to Tangible Book5.97 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.157364
BETA2.12424 52-week High/Low27.82 / 9.735 Stddev0.228448
View SEC Filings from EPZM instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 9 6 (0.39%)
13F Filers holding this stock: 140 45 (2.95%)
Aggregate 13F shares on 03/31/2020: 91.026 Million 44.16 Million
Aggregate 13F shares on 12/31/2019: 91.397 Million 43.739 Million
Percent change: -0.41% 0.96%
Funds creating new positions: 30 13
Funds Adding to an existing position: 50 15
Funds closing out their position: 23 9
Funds reducing their position: 47 16
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding EPZM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EPZM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

62 Thousand total shares from 1 transactions

Open Market Sells (S)

143.4 Thousand total shares from 10 transactions

Exercise Derivative Conversion (M)

122 Thousand total shares from 4 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MOTT DAVID M

  • Director
0 2020-07-01 7

SANDELL SCOTT D

  • 10% Owner
4,294,207 2020-06-30 0

BASKETT FOREST

  • 10% Owner
4,294,207 2020-06-30 0

CONROY KEVIN T

  • Director
7,602 2020-06-30 5

GOULD ROBERT J SEE REMARKS

  • Officer
  • Director
537,345 2020-06-25 0

BAZEMORE ROBERT B PRESIDENT & CEO

  • Officer
  • Director
250,098 2020-06-25 5

ROS MATTHEW SEE REMARKS

  • Officer
57,507 2020-06-25 6

GIORDANO MICHAEL F

  • Director
0 2020-06-25 1

AGARWAL SHEFALI CHIEF MEDICAL OFFICER

  • Officer
78,611 2020-06-25 7

BEAULIEU JOSEPH CORPORATE CONTROLLER

  • Officer
4,838 2020-06-25 6

TOMBESI PAOLO CHIEF FINANCIAL OFFICER

  • Officer
21,942 2020-06-25 7

BATE KENNETH

  • Director
0 2020-06-18 1

RHODES JASON P

  • Director
12,630,758 2020-06-16 0

SEIDENBERG BETH C

  • Director
1,904,233 2020-06-16 0

LEGORRETA PABLO G. CEO, CHAIRMAN OF THE BOARD

  • Officer
  • Director
0 2020-06-15 4

KERINS PATRICK J

  • 10% Owner
8,097,725 2020-06-10 0

ALLEN ANDREW R

  • Director
0 2020-06-09 2

POPS RICHARD F

  • Director
0 2020-05-29 1

GOLDFISCHER CARL

  • Director
0 2020-05-29 1

BOGLE GRANT C.

  • Director
0 2020-05-29 3

RICHON VICTORIA

  • Director
0 2020-05-29 3

LEGORRETA PABLO G.

RP MANAGEMENT, LLC

RPI FINANCE TRUST

  • Director
  • 10% Owner
9,166,667 2020-05-29 4

BARRIS PETER J

  • Director
6,420 2020-05-27 0

NEA PARTNERS 13, LIMITED PARTNERSHIP

NEA 13 GP, LTD

  • 10% Owner
4,059,376 2020-05-19 0

NEW ENTERPRISE ASSOCIATES 13 LP

  • 10% Owner
4,059,376 2020-05-19 0

KUTOK JEFFERY CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-04-01 2

BAY CITY CAPITAL LLC

BAY CITY CAPITAL MANAGEMENT V LLC

BAY CITY CAPITAL FUND V, L.P.

BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P.

  • 10% Owner
1,393,612 2020-03-16 0

BARRETT M JAMES

  • Director
0 2019-05-30 0

NEW ENTERPRISE ASSOCIATES 13 LP

NEA PARTNERS 13, LIMITED PARTNERSHIP

NEA 13 GP, LTD

  • 10% Owner
0 2019-01-22 0

VISWANATHAN RAVI

  • 10% Owner
5,000,000 2018-10-17 0

GRAF SUSAN E CHIEF BUSINESS OFFICER

  • Officer
0 2018-02-09 0

FLEMING SUZANNE SVP

  • Officer
0 2018-02-09 0

HO PETER TAI-CHING CHIEF DEVELOPMENT OFFICER

  • Officer
10,123 2017-10-24 0

SINGER ANDREW E. EVP & CFO

  • Officer
45,446 2017-08-09 0

COPELAND ROBERT A PRESIDENT OF RESEARCH AND CSO

  • Officer
31,538 2017-06-06 0

KOLLURI KRISHNA KITTU

  • 10% Owner
5,215,128 2016-12-19 0

WELLER HARRY R

  • 10% Owner
3,490,073 2016-10-31 0

DRANT RYAN D

  • 10% Owner
7,489,485 2015-06-05 0

GARBACZ STEPHEN PRINCIPAL ACCOUNTING OFFICER

  • Officer
13,073 2014-11-03 0

HEDRICK ERIC CHIEF MEDICAL OFFICER

  • Officer
429 2014-10-15 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

MOTT DAVID M - Director

2020-06-30 A 1,459 $16.06 a 84,060 191,019.00 direct

CONROY KEVIN T - Director

2020-06-30 A 693 $16.06 a 7,602 7,602.00 direct

TOMBESI PAOLO - Officer CHIEF FINANCIAL OFFICER

2020-06-26 S 1,805 $16.15 d 21,942 21,942.00 direct

BEAULIEU JOSEPH - Officer CORPORATE CONTROLLER

2020-06-26 S 317 $16.15 d 4,838 4,838.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-06-26 S 4,773 $16.15 d 250,098 250,098.00 direct

ROS MATTHEW - Officer SEE REMARKS

2020-06-26 S 2,728 $16.15 d 57,507 57,507.00 direct

AGARWAL SHEFALI - Officer CHIEF MEDICAL OFFICER

2020-06-26 S 1,805 $16.15 d 78,611 78,611.00 direct

MOTT DAVID M - Director

2020-06-26 P 62,019 $16.03 a 82,601 189,560.00 direct

AGARWAL SHEFALI - Officer CHIEF MEDICAL OFFICER

2020-06-25 A 6,000 a 80,416 78,611.00 direct

TOMBESI PAOLO - Officer CHIEF FINANCIAL OFFICER

2020-06-25 A 6,000 a 23,747 21,942.00 direct

BEAULIEU JOSEPH - Officer CORPORATE CONTROLLER

2020-06-25 A 1,050 a 5,155 4,838.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-06-25 A 10,500 a 254,871 250,098.00 direct

ROS MATTHEW - Officer SEE REMARKS

2020-06-25 A 6,000 a 60,235 57,507.00 direct

ROS MATTHEW - Officer SEE REMARKS

2020-06-18 M 68,651 d 104,787 51,798.00 direct yes

ROS MATTHEW - Officer SEE REMARKS

2020-06-18 S 68,651 $21.65 d 51,798 51,798.00 direct yes

ROS MATTHEW - Officer SEE REMARKS

2020-06-18 M 2,289 $12.45 a 54,087 51,798.00 direct yes

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-06-18 M 10,000 d 323,333 244,371.00 direct yes

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-06-18 M 10,000 $8.98 a 264,371 244,371.00 direct yes

ROS MATTHEW - Officer SEE REMARKS

2020-06-18 M 2,289 d 107,577 51,798.00 direct yes

ROS MATTHEW - Officer SEE REMARKS

2020-06-18 M 68,651 $9.58 a 120,449 51,798.00 direct yes

ROS MATTHEW - Officer SEE REMARKS

2020-06-18 S 41,063 $20.50 d 51,798 51,798.00 direct yes

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-06-18 S 10,000 $22.00 d 244,371 244,371.00 direct

MOTT DAVID M - Director see footnote

2020-06-18 J 67,662 a 106,959 127,541.00 indirect

ROS MATTHEW - Officer SEE REMARKS

2020-06-18 M 41,063 d 110,557 51,798.00 direct yes

ROS MATTHEW - Officer SEE REMARKS

2020-06-18 S 2,289 $22.00 d 51,798 51,798.00 direct yes

ROS MATTHEW - Officer SEE REMARKS

2020-06-18 M 41,063 $9.12 a 92,861 51,798.00 direct yes

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-06-18 S 10,000 $22.00 d 254,371 244,371.00 direct

GIORDANO MICHAEL F - Director

2020-05-29 A 14,013 a 14,013 0.00 direct

MOTT DAVID M - Director

2020-05-29 A 14,013 a 14,013 0.00 direct

BATE KENNETH - Director

2020-05-29 A 14,013 a 14,013 0.00 direct

RICHON VICTORIA - Director

2020-05-29 A 14,013 a 14,013 0.00 direct

POPS RICHARD F - Director

2020-05-29 A 14,013 a 14,013 0.00 direct

GOLDFISCHER CARL - Director

2020-05-29 A 14,013 a 14,013 0.00 direct

ALLEN ANDREW R - Director

2020-05-29 A 14,013 a 14,013 0.00 direct

CONROY KEVIN T - Director

2020-05-29 A 14,013 a 14,013 0.00 direct

LEGORRETA PABLO G. - Director - > 10% Owner

RP MANAGEMENT, LLC - Director - > 10% Owner

RPI FINANCE TRUST - Director - > 10% Owner

2020-05-29 A 14,103 a 14,103 9,166,667.00 direct

BOGLE GRANT C. - Director

2020-05-29 A 14,013 a 14,013 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments